![A graphic including a photo of Carey Anders, MD and a quote she gave to HemOnc Today: "If we don’t try these novel agents early on for patients with [central nervous system] disease, we won’t know if they work. So far, we have been surprised by what we found."](/sites/default/files/styles/freeform_scaled/public/2023-12/c_anders_hemonc_today.png?itok=re-7RIYx)
Duke Center for Brain and Spine Metastasis Center Co-Director Carey Anders, MD, was featured in the October issue of HemOnc Today.
The story, “Novel therapies, technologies give ‘hope for the future’ to those with brain metastasis,” focuses on the advances in treatment of brain metastases, including the inclusion of patients with brain metastases in clinical trials.
“There’s been a huge shift in terms of inclusion of patients with brain metastases in clinical trials, which I think is an advance in and of itself,” Anders told Healio. “If we don’t try these novel agents early on for patients with [central nervous system] disease, we won’t know if they work. So far, we have been surprised by what we found.”
Anders also discussed the effectiveness of antibody-drug conjugates in treatment and using molecular targets with anticancer therapies in the central nervous system.